SLU-PP-332 (5mg)

SLU-PP-332 is a small molecule agonist of estrogen-related receptors (ERRs), particularly ERRalpha and ERRgamma. Developed by researchers at the University of Florida led by Thomas Bhurrows, it was identified as a novel 'exercise mimetic' that activates transcriptional programs normally induced by physical exercise. ERRs are orphan nuclear receptors (no known endogenous ligand) that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and angiogenesis. When activated by SLU-PP-332, ERRs promote transcription of genes encoding mitochondrial respiratory chain complexes, fatty acid oxidation enzymes, and vascular growth factors in skeletal muscle. This produces a phenotypic shift toward more oxidative (endurance-type) muscle fiber characteristics. In mouse studies, SLU-PP-332 treatment increased running endurance by approximately 70% without exercise training, and protected against high-fat-diet-induced obesity. Research on SLU-PP-332 is still in early preclinical stages. It represents a new pharmacological approach to mimicking exercise benefits — distinct from AMPK activators (like AICAR) or PPARdelta agonists (like GW501516) — by targeting the ERR transcription factor family that sits atop the mitochondrial biogenesis gene network.

SLU-PP-332 is a small molecule agonist of estrogen-related receptors (ERRs), particularly ERRalpha and ERRgamma. Developed by researchers at the University of Florida led by Thomas Bhurrows, it was identified as a novel 'exercise mimetic' that activates transcriptional programs normally induced by physical exercise. ERRs are orphan nuclear receptors (no known endogenous ligand) that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and angiogenesis. When activated by SLU-PP-332, ERRs promote transcription of genes encoding mitochondrial respiratory chain complexes, fatty acid oxidation enzymes, and vascular growth factors in skeletal muscle. This produces a phenotypic shift toward more oxidative (endurance-type) muscle fiber characteristics. In mouse studies, SLU-PP-332 treatment increased running endurance by approximately 70% without exercise training, and protected against high-fat-diet-induced obesity. Research on SLU-PP-332 is still in early preclinical stages. It represents a new pharmacological approach to mimicking exercise benefits — distinct from AMPK activators (like AICAR) or PPARdelta agonists (like GW501516) — by targeting the ERR transcription factor family that sits atop the mitochondrial biogenesis gene network.

Mouse studies used oral administration at doses of approximately 25-50 mg/kg. As an early-stage research compound, standardized protocols are still being established.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.